Inamrinone Side Effects

Some side effects of inamrinone may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to inamrinone: intravenous solution

Along with its needed effects, inamrinone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking inamrinone:

• Dizziness
• irregular heartbeat
• low blood pressure

• Black, sticky stools
• blood in urine or stools
• burning at site of injection
• chest pain or discomfort
• loss of appetite
• pinpoint red spots on skin
• unusual bleeding or bruising
• weight loss
• yellow eyes or skin

Some side effects of inamrinone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

• Fever
• nausea or vomiting
• stomach pain

For Healthcare Professionals

Applies to inamrinone: intravenous solution

Hematologic

A potentially serious hematologic abnormality is thrombocytopenia. Reduced platelet counts have been seen in 20% to 46% of patients, but were rarely symptomatic. Thrombocytopenia appears to be related to the total daily dose and duration of infusion and generally has resolved within 2 to 4 days following amrinone withdrawal.

Rare cases of hemorrhagic pericardial effusions and splenomegaly have been associated with inamrinone-induced thrombocytopenia.

Thrombocytopenia may not necessitate drug discontinuation. It is recommended that patients whose platelet count is less than 150,000/mm3 be carefully monitored.

There is limited evidence to support either a direct drug-associated platelet effect or platelet destruction due to an IgG antiplatelet antibody. The exact mechanism is not known.

Cardiovascular

Cardiovascular side effects have included hypotension, arrhythmias, and heart failure. Infusion-related hypotension occurred in 1% to 3% of patients. New cases of sustained atrial and ventricular arrhythmias or worsened congestive heart failure have been reported in 9% of patients. Some data are from uncontrolled studies and a casual relationship may be difficult to determine due to the serious underlying cardiac disease of the study population. Chest pain is reported in 0.2% of patients.

Gastrointestinal

Gastrointestinal symptoms of general abdominal pain, anorexia, diarrhea, nausea, or vomiting have occurred in up to 27% of patients. Rare complaints of smell or taste loss have been reported.

Nervous system

Nervous system side effects have included dizziness, headache, lightheadedness, or paresthesias in approximately 20% of patients. Somnolence and fatigue are reported in 3% and 15% of patients, respectively.

Dermatologic

Dermatologic side effects have included skin dryness and yellow nail discoloration.

Hepatic

Hepatic toxicity has been reported after long-term oral use of inamrinone. In a study of 173 patients, approximately 20% developed elevated serum SGOT or LDH levels. Hepatotoxicity associated with short-term intravenous use has occurred rarely. Elevations in bilirubin and jaundice have been reported.

Cases of reproducible and reversible hepatitis have been associated with inamrinone use. In some cases, elevated serum transaminases and LDH were accompanied by bilateral pulmonary infiltrates and eosinophilia suggestive of an allergic drug reaction.

Hypersensitivity

Hypersensitivity to amrinone may present as a generalized viral-like syndrome characterized by myalgias, arthralgias, and fever. This syndrome may be accompanied by myositis, diffuse pulmonary infiltrates, pruritus, and confusion.

Respiratory

Respiratory infections have been reported in up to 22% of patients.

Local

Local intravenous site injection pain has been reported in 0.2% of patients. This may be minimized by diluting the inamrinone infusate in normal or half-normal saline to a final concentration of 1 to 3 mg/mL.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.